NY-ENERGY-IMPACT
7.4.2021 13:51:06 CEST | Business Wire | Press release
Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, announced Shell Ventures, EDF, and DSD as the latest European leaders to join its coalition focused on the advancement of technologies accelerating global decarbonization. EIP’s coalition collaborates by sharing insights, investing in innovative and transformative businesses, and amplifying entrepreneurs' growth through dedicated partnerships.
Shell Ventures, EDF, and DSD represent a broad cross-section of the European energy industry. Their participation in EIP’s global coalition displays a commitment and shared mission to accelerate the pace of innovation and rapidly scale the adoption of critical climate solutions. They join a diverse group of industry leaders across the energy, mobility and sustainability industries including EWE, Fortum, Enterprise Holdings, AGL, Nysno, and Tronder Energie.
“We want to welcome Shell Ventures, EDF, and DSD as our newest partners to EIP’s European coalition,” said Matthias Dill, Managing Partner at Energy Impact Partners. “The experience that these innovative companies bring will allow us to better accelerate existing climate solutions and to create new technologies to facilitate a global energy transition.”
“Shell Ventures is looking forward to actively participating in EIP’s global investment platform. As leaders in the energy transition, both Shell Ventures and EIP have previously co-invested in several ventures. The energy and the climate challenge are extremely complex and will require strong collaboration to scale promising solutions and create real impact. EIP’s strong convening power is therefore essential to help accelerate the shift to a lower carbon future.” (Geert van de Wouw, Vice President Shell Ventures)
“EDF Group is very enthusiastic about joining, along with some major industrial energy players, the European coalition of EIP devoted to identifying and supporting the development of innovative carbon neutrality oriented ventures. This partnership will enable us to detect new levers for growth in alignment with the strategy of EDF to support and accelerate the climate transition of our customers.” (Guillaume Lesueur, Head of Investments, EDF Pulse Croissance)
“DSD Group are very pleased to join this EIPs European Coalition from Norway. Innovation and energy efficient solutions have always been in the core of DSD’s 166-year long existence. We invest in people who want to search and develop new ideas, create world-leading technology and contribute to a sustainable future. We believe the unique approach that EIP Global & European Coalition represents, will help accelerating the green energy transition, and we are grateful for EIP’s effort and initiative for making this happen. Together and in collaboration with many innovative industrial players world-wide we really look forward to working for a more carbon-neutral world.” (Yuhong Jin Hermansen, Chairman of the Board, DSD AS)
For more information on EIP, please visit www.energyimpactpartners.com .
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, and Cologne. For more information on EIP, please visit www.energyimpactpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005562/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom